GDF15 and type 2 diabetes mellitus: Chronic low-grade inflammation characterises both conditions, and the subsequent reduction in GDF15 after BS may indicate resolution of systemic inflammatory processes, along with improved metabolic status following the remission of T2D and better control of HBP.